Hematologic effects of linezolid: Summary of clinical experience

Stanton L. Gerson; Sheldon L. Kaplan; Jon B. Bruss; Vu Le; Felix M. Arellano; Barry Hafkin; David J. Kuter

doi:10.1128/AAC.46.8.2723-2726.2002

Hematologic effects of linezolid: Summary of clinical experience

Stanton L. Gerson, Sheldon L. Kaplan, Jon B. Bruss, Vu Le, Felix M. Arellano, Barry Hafkin, David J. Kuter

Research output: Contribution to journal › Article › peer-review

409 Scopus citations

Abstract

Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at ≥2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.

Original language	English (US)
Pages (from-to)	2723-2726
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	46
Issue number	8
DOIs	https://doi.org/10.1128/AAC.46.8.2723-2726.2002
State	Published - 2002

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.46.8.2723-2726.2002

Cite this

@article{de2ca263609b4a1a98bbe1db36f7f3b5,

title = "Hematologic effects of linezolid: Summary of clinical experience",

abstract = "Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at ≥2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.",

author = "Gerson, \{Stanton L.\} and Kaplan, \{Sheldon L.\} and Bruss, \{Jon B.\} and Vu Le and Arellano, \{Felix M.\} and Barry Hafkin and Kuter, \{David J.\}",

year = "2002",

doi = "10.1128/AAC.46.8.2723-2726.2002",

language = "English (US)",

volume = "46",

pages = "2723--2726",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "8",

}

TY - JOUR

T1 - Hematologic effects of linezolid

T2 - Summary of clinical experience

AU - Gerson, Stanton L.

AU - Kaplan, Sheldon L.

AU - Bruss, Jon B.

AU - Le, Vu

AU - Arellano, Felix M.

AU - Hafkin, Barry

AU - Kuter, David J.

PY - 2002

Y1 - 2002

N2 - Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at ≥2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.

AB - Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at ≥2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.

UR - https://www.scopus.com/pages/publications/0035992065

UR - https://www.scopus.com/inward/citedby.url?scp=0035992065&partnerID=8YFLogxK

U2 - 10.1128/AAC.46.8.2723-2726.2002

DO - 10.1128/AAC.46.8.2723-2726.2002

M3 - Article

C2 - 12121967

AN - SCOPUS:0035992065

SN - 0066-4804

VL - 46

SP - 2723

EP - 2726

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 8

ER -

Hematologic effects of linezolid: Summary of clinical experience

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this